Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial

Author:

Lee Chan Joo1ORCID,Kang Woong Chol2,Ihm Sang Hyun3,Sohn Il Suk4,Woo Jong Shin5ORCID,Kim Jin Won6,Hong Soon Jun7,Choi Jung Hyun8,Suh Jung‐Won9,Seo Jae‐Bin10,Doh Joon‐Hyung11,Son Jung‐Woo12,Park Jae‐Hyeong13,Lee Ju‐Hee14,Hong Young Joon15,Heo Jung Ho16,Shin Jinho17,Kang Seok‐Min1

Affiliation:

1. Division of Cardiology Department of Internal Medicine Severance Hospital Yonsei University College of Medicine Seoul South Korea

2. Department of Cardiology Gil Hospital Gachon University Incheon South Korea

3. Division of Cardiology Department of Internal Medicine Bucheon St. Mary's Hospital The Catholic University of Korea Seoul South Korea

4. Department of Cardiology Kyung Hee University Hospital at Gangdong Seoul South Korea

5. Department of Internal Medicine Kyung Hee University College of Medicine Kyung Hee University Medical Center Seoul South Korea

6. Division of Interventional Cardiology Cardiovascular Center Korea University Guro Hospital Seoul South Korea

7. Division of Cardiology Department of Internal Medicine Korea University Anam Hospital Seoul South Korea

8. Division of Cardiology Department of Internal Medicine Pusan National University School of Medicine Busan South Korea

9. Division of Cardiology Department of Internal Medicine Seoul National University College of Medicine Seoul National University Bundang Hospital Seongnam South Korea

10. Division of Cardiology Department of Internal Medicine Boramae Medical Center Seoul National University College of Medicine Seoul South Korea

11. Division of Cardiology Department of Medicine Inje University Ilsan Paik Hospital Goyang South Korea

12. Division of Cardiology Department of Internal Medicine Wonju Severance Christian Hospital Yonsei University Wonju College of Medicine Wonju South Korea

13. Department of Cardiology in Internal Medicine, Chungnam National University Hospital School of Medicine, Chungnam National University Daejeon South Korea

14. Division of Cardiology Department of Internal Medicine Chungbuk National University Hospital Chungbuk National University College of Medicine Cheongju South Korea

15. Division of Cardiology Chonnam National University Medical School Chonnam National University Hopital Gwangju South Korea

16. Division of Cardiology Department of Internal Medicine Kosin University Gospel Hospital Busan South Korea

17. Division of Cardiology Department of Internal Medicine Hanyang University Seoul Hospital Hanyang University College of Medicine Seoul South Korea

Abstract

AbstractThis study aimed to compare and evaluate the efficacy of the blood pressure (BP) control and cholesterol‐lowering effects and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe versus rosuvastatin and ezetimibe double therapy or telmisartan single therapy in dyslipidemia patients with hypertension. After a wash‐out/therapeutic lifestyle change period of ≥4 weeks, a total of 100 eligible patients were randomized and received one of three treatments for 8 weeks: (1) telmisartan 80 mg/rosuvastatin 20 mg/ezetimibe 10 mg (TRE), (2) rosuvastatin 20 mg/ezetimibe 10 mg (RE), or (3) telmisartan 80 mg (T). The primary endpoint was the efficacy evaluation of TRE by comparing changes in mean sitting systolic blood pressure (msSBP) and mean percentage change in low‐density lipoprotein‐C (LDL‐C) from baseline after 8 weeks of treatment.The least square (LS) mean (SE) changes in msSBP at 8 weeks compared with baseline were −23.02 (3.04) versus −7.18 (3.09) mmHg in the TRE and RE groups, respectively (p < .0001), and −25.80 (2.74) versus −14.92 (2.65) mmHg in the TRE and T groups, respectively (p = .0005). The percentage changes in the mean (SD) LDL‐C at 8 weeks compared with baseline were −54.97% (3.49%) versus −0.17% (3.23%) in the TRE and T groups, respectively (p < .0001). No serious adverse events occurred, and no statistically significant differences in the incidence of overall AEs and adverse drug reactions occurred among the three groups.TRE therapy significantly decreased msSBP and LDL‐C compared to RE or T therapy with comparable safety and tolerability profiles.

Publisher

Wiley

Reference51 articles.

1. World Health Organization.(2021 June). “Cardiovascular diseases (CVDs).”https://www.who.int/en/news‐room/fact‐sheets/detail/cardiovascular‐diseases‐(cvds)

2. The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis

3. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins

4. Dyslipidemia Fact Sheet in South Korea, 2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3